furo<2,3-c>quinoline | 232-99-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 喹啉及其衍生物
• 英文名称: furo<2,3-c>quinoline
• 英文别名: furo[2,3-c]quinoline
• CAS: 232-99-5
• 化学式: C₁₁H₇NO
• mdl: MFCD18449134
• 分子量: 169.183
• InChiKey: JPFGSAMQRNUJDQ-UHFFFAOYSA-N

物化性质

• 沸点：
  108 °C(Press: 0.1 Torr)
• 密度：
  1.265±0.06 g/cm3(Predicted)
• 熔点：
  47-49 °C

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  26
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  furo<2,3-c>quinoline 在 间氯过氧苯甲酸 作用下， 以 氯仿 为溶剂， 反应 4.0h， 生成 furo<2,3-c>quinoline N-oxide
  参考文献：
  名称：

  Exquisite Selectivity for Human Toll-Like Receptor 8 in Substituted Furo[2,3-c]quinolines

  摘要：

  Toll-like receptor (TLR)-8 agonists activate adaptive immune responses by inducing robust production of T helper 1-polarizing cytokines, suggesting that TLR8-active compounds may be promising candidate adjuvants. We synthesized and evaluated hitherto unexplored furo[2,3-d]quinolines and regioisomeric furo[3,2-c]quinolines derived via a tandem, one-pot Sonogashira coupling and intramolecular 5-endo-dig cyclization strategy in a panel of primary screens. We observed a pure TLR8-agonistic activity profile in select furo[2,3-c]quinolines, with maximal potency conferred by a C2-butyl group (EC50 = 1.6 mu M); shorter, longer, or substituted homologues as well as compounds bearing C1 substitutions were inactive, which was rationalized by docking studies using the recently described crystal structure of human TLR8. The best-in-class compound displayed,prominent proinflammatory cytokine induction (including interleukin-12 and interleukin-18), but was bereft of interferon-alpha inducing properties, confirming its high selectivity for human TLR8.

  DOI：

  10.1021/jm400694d
• 作为产物：
  描述：

  3-羟基喹啉 在 copper(l) iodide 、 四(三苯基膦)钯 、 碘 、 三乙胺 、 potassium iodide 、 sodium hydroxide 作用下， 以 水 、 乙腈 为溶剂， 反应 15.0h， 生成 furo<2,3-c>quinoline
  参考文献：
  名称：

  Exquisite Selectivity for Human Toll-Like Receptor 8 in Substituted Furo[2,3-c]quinolines

  摘要：

  Toll-like receptor (TLR)-8 agonists activate adaptive immune responses by inducing robust production of T helper 1-polarizing cytokines, suggesting that TLR8-active compounds may be promising candidate adjuvants. We synthesized and evaluated hitherto unexplored furo[2,3-d]quinolines and regioisomeric furo[3,2-c]quinolines derived via a tandem, one-pot Sonogashira coupling and intramolecular 5-endo-dig cyclization strategy in a panel of primary screens. We observed a pure TLR8-agonistic activity profile in select furo[2,3-c]quinolines, with maximal potency conferred by a C2-butyl group (EC50 = 1.6 mu M); shorter, longer, or substituted homologues as well as compounds bearing C1 substitutions were inactive, which was rationalized by docking studies using the recently described crystal structure of human TLR8. The best-in-class compound displayed,prominent proinflammatory cytokine induction (including interleukin-12 and interleukin-18), but was bereft of interferon-alpha inducing properties, confirming its high selectivity for human TLR8.

  DOI：

  10.1021/jm400694d

文献信息

• [EN] TOLL-LIKE RECEPTOR 8 AGONISTS<br/>[FR] AGONISTES DES RÉCEPTEURS TOLL-LIKE 8
  申请人：UNIV KANSAS

  公开号：WO2015095780A1

  公开（公告）日：2015-06-25

  Compounds described herein can be used for therapeutic purposes. The compounds can be TLR agonists, such as TLR8 agonists. The compounds can be included in pharmaceutical compositions and used for therapies were being a TLR8 agonist is useful. The pharmaceutical compositions can include any ingredients, such as carries, diluents, excipients, fillers or the like that are common in pharmaceutical compositions. The compounds can be those illustrated or described herein as well as derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combinations thereof. As such, the compounds can be used as adjuvants in vaccines as well as for other therapeutic purposes described herein. The compounds can have any one of the formulae described herein or derivative thereof.

  本文描述的化合物可用于治疗目的。这些化合物可以是TLR激动剂，例如TLR8激动剂。这些化合物可以包含在药物组合物中，并用于治疗需要TLR8激动剂的情况。药物组合物可以包括任何成分，例如载体、稀释剂、赋形剂、填料或其他在药物组合物中常见的成分。这些化合物可以是本文所述的化合物，以及其衍生物、前药、盐、立体异构体，或在任何手性中心具有任何手性，或互变异构体、多晶形态、溶剂合剂，或其组合。因此，这些化合物可以用作疫苗的辅助剂，以及用于本文描述的其他治疗目的。这些化合物可以具有本文描述的任何一个化学式或其衍生物。
• [EN] ANTIBODY CONSTRUCT CONJUGATES<br/>[FR] CONJUGUÉS DE CONSTRUCTION D'ANTICORPS
  申请人：SILVERBACK THERAPEUTICS INC

  公开号：WO2018227023A1

  公开（公告）日：2018-12-13

  Various compositions are disclosed. The compositions of composition-immune stimulatory compound conjugates are also provided. Additionally provided are the methods of preparation and uses of the composition-immune stimulatory compound conjugates. This includes methods for treating disorders, such as cancer.

  各种组合物被揭示。还提供了组合物 - 免疫刺激化合物偶联物的组合物。此外，还提供了组合物 - 免疫刺激化合物偶联物的制备方法和用途。这包括治疗疾病的方法，如癌症。
• Toll-like receptor 8 agonists
  申请人：The University Of Kansas

  公开号：US10654807B2

  公开（公告）日：2020-05-19

  Compounds described herein can be used for therapeutic purposes. The compounds can be TLR agonists, such as TLR8 agonists. The compounds can be included in pharmaceutical compositions and used for therapies were being a TLR8 agonist is useful. The pharmaceutical compositions can include any ingredients, such as carries, diluents, excipients, fillers or the like that are common in pharmaceutical compositions. The compounds can be those illustrated or described herein as well as derivative thereof, prodrug thereof, salt thereof, or stereoisomer thereof, or having any chirality at any chiral center, or tautomer, polymorph, solvate, or combinations thereof. As such, the compounds can be used as adjuvants in vaccines as well as for other therapeutic purposes described herein. The compounds can have any one of the formulae described herein or derivative thereof.

  本文所述化合物可用于治疗目的。这些化合物可以是 TLR 激动剂，如 TLR8 激动剂。这些化合物可以包含在药物组合物中，用于治疗TLR8激动剂有用的疾病。药物组合物可以包括任何成分，例如药物组合物中常见的载体、稀释剂、赋形剂、填料或类似物。化合物可以是本文图示或描述的化合物，也可以是其衍生物、原药、盐或立体异构体，或在任何手性中心具有任何手性的化合物，或同系物、多晶型物、溶胶或其组合。因此，这些化合物可用作疫苗佐剂，也可用于本文所述的其他治疗目的。这些化合物可以具有本文所述的任何一种式子或其衍生物。
• Human TLR8-selective agonists
  申请人：UNIVERSITY OF KANSAS

  公开号：US11130736B2

  公开（公告）日：2021-09-28

  The disclosure provides human toll-like receptor modulators of general Formula (II), wherein R1, R2, R3, R4, R5, R6, R7, R8 are defined herein.

  本公开提供通式（II）的人类收费样受体调节剂，其中 R1、R2、R3、R4、R5、R6、R7、R8 在本文中定义。
• Yang, Youhua, Synthetic Communications, 1989, vol. 19, # 5and6, p. 1001 - 1008
  作者：Yang, Youhua

  DOI：——

  日期：——